Epidermal growth factor receptor

Epidermal growth factor receptor
Boghog · Public domain · source
Name	Epidermal growth factor receptor
Location	Cell membrane
Function	Receptor tyrosine kinase

Epidermal growth factor receptor is a transmembrane receptor tyrosine kinase that mediates responses to extracellular peptide growth factors and regulates cell proliferation, differentiation, survival, and migration. It is central to signaling networks studied in molecular biology, oncology, developmental biology, and pharmacology, and has been the focus of research at institutions such as National Institutes of Health, Cold Spring Harbor Laboratory, Dana-Farber Cancer Institute, Broad Institute, and European Molecular Biology Laboratory. Key findings on its structure, ligands, and role in disease have been reported in journals associated with Nature Publishing Group, Science (journal), and Cell Press.

Structure and biochemical properties

The receptor is a single-pass transmembrane protein with an extracellular ligand-binding domain, a single transmembrane helix, an intracellular tyrosine kinase domain, and regulatory C-terminal tails, features resolved using methods developed by teams at Max Planck Society, Laboratory of Molecular Biology, and Rutherford Appleton Laboratory. Crystal structures and cryo-EM reconstructions reported by groups at University of Oxford, Massachusetts Institute of Technology, Harvard University, and Stanford University revealed the asymmetric kinase dimer interface and activation loop, complementing biochemical analyses from laboratories at University of Cambridge, Yale University, Johns Hopkins University, and Columbia University. Mutations in the kinase domain characterized in cohorts from Memorial Sloan Kettering Cancer Center, Mayo Clinic, and Cleveland Clinic alter ATP binding and autophosphorylation kinetics, properties investigated using assays refined at University of California, Berkeley, University of Toronto, and University College London.

Ligands and activation mechanisms

EGFR binds several peptide ligands including EGF, transforming growth factor-alpha, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, and epiregulin, ligands first characterized in studies at Salk Institute, Weizmann Institute of Science, and Karolinska Institutet. Ligand binding induces receptor dimerization or higher-order oligomerization, a mechanism explored alongside receptor interactions with other family members such as HER2, HER3, and HER4 by researchers at University of Pennsylvania, Vanderbilt University, and University of Michigan. Activation is modulated by post-translational modifications including phosphorylation, ubiquitination, and glycosylation, with regulatory enzymes and adaptors studied at University of Zurich, University of Geneva, and ETH Zurich. Endocytic trafficking, recycling, and degradation pathways that influence signaling amplitude involve proteins examined at Max Planck Institute of Biochemistry, Fred Hutchinson Cancer Center, and Institute Pasteur.

Intracellular signaling pathways

Upon activation, the receptor recruits adaptor proteins and enzymes including GRB2, SHC, SOS, PI3K, PLCγ, and STATs, initiating cascades such as the RAS–RAF–MEK–ERK and PI3K–AKT–mTOR pathways, signaling modules extensively dissected by teams at European Molecular Biology Laboratory, Howard Hughes Medical Institute, and Cold Spring Harbor Laboratory. Cross-talk with receptor tyrosine kinases and G protein–coupled receptors investigated at University of California, San Francisco, University of Texas MD Anderson Cancer Center, and National Cancer Institute shapes cellular outcomes. Downstream transcriptional programs involving ETS-family and AP-1 transcription factors, and modulation by chromatin remodelers studied at Broad Institute, Wellcome Trust Sanger Institute, and University of Edinburgh determine proliferation, survival, and differentiation responses.

Physiological roles and tissue distribution

EGFR signaling governs epithelial development, organogenesis, wound healing, and homeostasis in tissues such as skin, lung, liver, and gastrointestinal tract, roles elucidated in developmental studies at Karolinska Institutet, University of California, San Diego, and Tokyo University. Its expression and activity are characterized in normal and specialized cells including keratinocytes, bronchial epithelial cells, hepatocytes, and intestinal crypt cells in research from Seoul National University, Peking University, and University of São Paulo. Physiological processes involving EGFR intersect with pathways studied in endocrinology and regenerative medicine at Johns Hopkins University School of Medicine, Yale School of Medicine, and University of Melbourne.

Role in cancer and other diseases

Aberrant EGFR signaling contributes to oncogenesis in non-small cell lung carcinoma, glioblastoma, colorectal cancer, head and neck squamous cell carcinoma, and other malignancies, clinical correlations reported by teams at Memorial Sloan Kettering Cancer Center, Royal Marsden Hospital, Instituto Nacional de Cancerologia (Mexico), and Institut Gustave Roussy. Somatic mutations, amplifications, and extracellular domain variants influence responsiveness to targeted therapies in cohorts from Dana-Farber Cancer Institute, MD Anderson Cancer Center, and City of Hope. EGFR is implicated in diseases beyond cancer including pulmonary fibrosis, psoriasis, and Alzheimer's disease in studies from Imperial College London, Mount Sinai Health System, and University of Pittsburgh Medical Center. Resistance mechanisms involving secondary mutations, bypass signaling, and phenotypic plasticity have been characterized in work from University of Chicago, Stanford Cancer Institute, and Sloan Kettering Institute.

Diagnostic and therapeutic targeting

EGFR is a biomarker and therapeutic target assessed using immunohistochemistry, fluorescence in situ hybridization, PCR-based assays, and next-generation sequencing platforms developed at Illumina, Roche Diagnostics, and Thermo Fisher Scientific. Therapeutics include monoclonal antibodies such as cetuximab and panitumumab, and tyrosine kinase inhibitors such as gefitinib, erlotinib, afatinib, osimertinib, and dacomitinib, agents evaluated in clinical trials overseen by organizations like Food and Drug Administration, European Medicines Agency, National Cancer Institute, and cooperative groups including SWOG and EORTC. Combination strategies with chemotherapy, radiation, immune checkpoint inhibitors (investigated at Memorial Sloan Kettering Cancer Center and MSKCC), and antibody–drug conjugates from industry partners such as AstraZeneca and Roche aim to overcome resistance.

Experimental methods and model systems

Structural studies utilize X-ray crystallography and cryo-electron microscopy performed at facilities like Diamond Light Source, European Synchrotron Radiation Facility, and Argonne National Laboratory. Biochemical and cellular assays employ recombinant proteins, ligand-binding assays, phosphorylation assays, and live-cell imaging developed at Cold Spring Harbor Laboratory and Harvard Medical School. Genetically engineered mouse models, patient-derived xenografts, organoids, and cell lines such as HeLa, A549, PC9, and H1975 are used in preclinical studies at Jackson Laboratory, Francis Crick Institute, RIKEN, and Max Planck Institute for Molecular Genetics. High-throughput screening and CRISPR/Cas9 genetic perturbation screens at Broad Institute and Sanger Institute map genetic interactions and therapeutic vulnerabilities.

Category:Receptor tyrosine kinases